Immunomodulation in sepsis: State of the art and future perspective

Immunotherapy

Volumn 3, Issue 1, 2011, Pages 117-128

  Antonopoulou, Anastasia ^a   Giamarellos Bourboulis, Evangelos J ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

activated protein C; anti TNF antibodies; antiendotoxin antibodies; clarithromycin; cytokines; immunonutrition; sepsis

Indexed keywords

ANTITHROMBIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BIOSIMAMOSE; CLARITHROMYCIN; CORTICOSTEROID; DROTRECOGIN; ERITORAN; FLUDROCORTISONE; GR 270773; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN ANTAGONIST; HYDROCORTISONE; IMMUNOGLOBULIN G; INSULIN; MACROLIDE; METHYLPREDNISOLONE; PLACEBO; POLYMYXIN B; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RESATORVID; SELECTIN ANTAGONIST; SELENIUM; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ULINASTATIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; BLEEDING; BRONCHIECTASIS; BRONCHIOLITIS; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIUM; ENZYME PHOSPHORYLATION; GLYCEMIC CONTROL; HEMOFILTRATION; HUMAN; IMMUNOMODULATION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG FIBROSIS; MENINGOCOCCOSIS; META ANALYSIS (TOPIC); NONHUMAN; NUTRITION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; T LYMPHOCYTE; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; GLYCOPROTEINS; HUMANS; IMMUNOMODULATION; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; THYMOSIN;

EID: 78650568172     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.82     Document Type: Review

References (84)

1. Dellinger RP, Carlet JM, Masur H et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32(3), 858-873 (2004). nn First published guidelines for severe sepsis; immunomodulation has been officially recognized as an everyday clinical practice. (Pubitemid 38344143)
2. Galley HF, Howdle PD, Barry E, Walker BE, Nigel R, Webster NR: The effects of intravenous antioxidants in patients with septic shock. Free Radic. Biol. Med. 23(5), 768-774 (1997). (Pubitemid 27364871)
3. Sandor F, Buc M: Toll-like receptors: structure, function and their ligands. Folia Biol. 51, 148-156 (2005). (Pubitemid 41645216)
4. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007).
5. Zhao Q, Wang X, Nelin LD et al.: MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 203(1), 131-140 (2006). (Pubitemid 43139652)
6. Castellheim A, Brekke O-L, Espevik T, Harboe M, Mollnes TE: Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand. J. Immunol. 69, 479-491 (2009).
7. Nduka OO, Parrillo JE: Pathophysiology of septic shock. Crit. Care Clin. 25(4), 677-702 (2009).
8. Netea MG, Simon A, van de Veerdonk F et al.: IL-1b processing in host defense: beyond the inflammasomes. PLoS Pathol. 6(2), E1000661 (2010).
9. Ward NS, Casserly B, Ayala A: The compensatory anti-inflammatory syndrome (CARS) in critically-ill patients. Clin. Chest Med. 29(4), 617-628 (2008).
10. Miller AC, Rashid RM, Elamin EM: The 'T' in trauma: the helper T-cell response and the role of immunomodulation in trauma and burn patients. J. Trauma 63, 1407-1417 (2007).
11. van der Poll T: Tissue factor as an initiator of coagulation and inflammation in the lung. Crit. Care 12(Suppl. 6), S3-S11 (2008).
12. Nick JA, Coldren CD, Geraci MW et al.: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophils chemotaxis. Blood 104, 3878-3885 (2004).
13. Bunnell E, Lynn M, Habet K et al.: A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit. Care Med. 28(8), 2713-2720 (2000).
14. Freeman BD, Natanson C: Anti-inflammatory therapies in sepsis and septic shock. Expert Opin. Investig. Drugs 9, 1651-1663 (2000). (Pubitemid 30433723)
15. Reinhart K, Glück T, Ligtenberg J et al.: CD14 receptor occupancy in severe sepsis: results of a Phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med. 32(5), 1100-1108 (2004). (Pubitemid 38620975)
16. Verbon A, Dekkers PEP, Ten Hove T et al.: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J. Immunol. 16, 3599-3605 (2001). (Pubitemid 33117366)
17. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34, 1084-1093 (2002). (Pubitemid 34289681)
18. Srivastava A, Casey H, Johnson N et al.: Recombinant bactericidal/ permeability-increasing protein rBPI21 protects against pneumococcal disease. Infect. Immun. 75, 342-349 (2007). (Pubitemid 46047910)
19. Dellinger RP, Tomayko JF, Angus DC et al.: Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a Phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit. Care Med. 37(11), 2929-2938 (2009).
20. Mullarkey M, Rose JR, Bristol J et al.: Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304 (3), 1093-1102 (2003). (Pubitemid 36254422)
21. Tidswell M, Tillis W, LaRosa SP et al.: Phase II trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38(1), 72-83 (2010). n Eritoran tetrasodium is a promising novel approach of immunomodulation in sepsis.
22. Bennett-Guerrero E, Grocott HP, Levy JH et al.: A Phase II, double-blind, placebo-controlled, ascending dose study of eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 104(2), 378-383 (2007). (Pubitemid 46146745)
23. Rice TW, Wheeler AP, Bernard GR et al.: A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38(8), 1685-1694 (2010).
24. Rice TW, Wheeler AP, Morris PE et al.: Safety and efficacy of affinity-purified, antitumor necrosis-a ovine Fab for injection (CytoFab) in severe sepsis. Crit. Care Med. 34(9), 2271-2281 (2006).
25. Opal SM, Fisher CJ Jr, Dhainaut JF et al.: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator group. Crit. Care Med. 25(7), 1115-1124 (1997).
26. Kumar A, Zanotti S, Bunnell G et al.: Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response. Crit. Care Med. 33(2), 331-340 (2005). (Pubitemid 40216546)
27. Emonts M, Sweep FCGJ, Grebenchtchikov N et al.: Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin. Infect. Dis. 44, 1321-1328 (2007). (Pubitemid 46717294)
28. Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ: Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann. NY Acad. Sci. 1144, 210-236 (2008).
29. Angus DC, Yang LH, Kong L et al.: Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit. Care Med. 35(4), 1061-1067 (2007). (Pubitemid 46598956)
30. Vincent JL, Spapen H, Bakker J et al.: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. 28(3), 638-642 (2000). (Pubitemid 30174255)
31. Seam N, Suffredini AF: Mechanisms of sepsis and insights from clinical trials. Drug Discov. Today Dis. Mech. 4(2), 83-93 (2007). (Pubitemid 351966332)
32. Bone RC, Fisher CJ Jr, Clemmer TP et al.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317(11), 653-658 (1987).
33. Sprung CL, Caralis PV, Marcial EH et al.: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med. 311(18), 1137-1143 (1984).
34. Briegel J, Jochum M, Gippner-Steppert M, Thiel M: Immunomodulation in septic shock: hydrocortisone differentially modulates cytokine responses. J. Am. Soc. Nephrol. 12, S70-S74 (2001). (Pubitemid 32119058)
35. Annane D, Sébille V, et al.: Effect of treatment with low-dose hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7), 862-871 (2002). nn First study revealing the benefit of steroid replacement in septic shock.
36. Lipiner-Friedman D, Sprung CL, Laterre PF et al.: Adrenal function in sepsis: the retrospective CORTICUS cohort study. Crit. Care Med. 35(4), 1012-1018 (2007). (Pubitemid 46598949)
37. Sprung CL, Annane D, Keh D et al.: Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 358, 111-124 (2008).
38. Marik PE, Pastores SM, Annane D et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency of critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med. 36(6), 1937-1949 (2008).
39. Krogh-Madsen R, Plomgaard P, Akerstrom T et al.: Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am. J. Physiol. Endocrinol. Metab. 294, E371-E379 (2008). (Pubitemid 351231464)
40. Van den Berghe G, Schetz M, Vlasselaers D et al.: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J. Clin. Endocrinol. Metabol. 94, 3163-3170 (2009).
41. Van den Berghe G, Wilmer A, Hermans G et al.: Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354, 449-461 (2006). (Pubitemid 43200296)
42. Brunkhorst FM, Engel C, Bloos F et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N. Engl. J. Med. 358, 125-139 (2008).
43. The NICE-SUGAR study investigators: Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360, 1283-1297 (2009).
44. Langouche L, Meersseman W, Vander Perre S et al.: Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients. Crit. Care Med. 36(5), 1475-1480 (2008). (Pubitemid 351620651)
45. Gonano C, Sitzwohl C, Meitner E et al.: 4-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Crit. Care 10, R160 (2006). (Pubitemid 47087009)
46. Matyal R, Mahmood F, Park KW: Tifacogin, recombinant tissue factor pathway inhibitor. Int. Anesthesiol. Clin. 43(2), 135-144 (2005). (Pubitemid 40571583)
47. Wiedermann CJ: Gerinnungsaktive substanzen als sepsistherapeutika erfolg und misserfolg. Internist 48, 537-544 (2007).
48. Dhainaut JF, Laterre PF, Janes JM et al.: Drotrecogin α (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 29, 894-903 (2003).
49. Bernard GR, Vincent JL, Laterre PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344(10), 699-709 (2001). nn Survival benefit is demonstrated for the administration of recombinant human activated protein C in severe sepsis. (Pubitemid 32204987)
50. Vincent JL, Bernard GR, Beale R et al.: Drotrecogin α (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med. 33(10), 2266-2277 (2005). (Pubitemid 41437481)
51. Abraham E, Laterre PF, Garg R et al.: Drotrecogin α (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353, 1332-1341 (2005). (Pubitemid 41362701)
52. Silva E, de Figueiredo LF, Colombari F. Prowess-shock trial: a protocol overview and perspectives. Shock 34(Suppl. 1), 48-53 (2010).
53. Mayr FB, Firbas C, Leitner JM et al.: Effects of the pan-selectin antagonist bimosiamose (Tbc1269) in experimental human endotoxemia. Shock 29(4), 475-482 (2008). (Pubitemid 351416801)
54. Angstwurm MWA, Engelmann L, Zimmermann T et al.: Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe inflammatory response syndrome, sepsis and septic shock. Crit. Care Med. 35(1), 118-126 (2007). (Pubitemid 46035686)
55. Forceville X, Laviolle B, Annane D et al.: Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, Phase II study. Critical Care 11, R73-R82 (2007). (Pubitemid 47261019)
56. Peng Y, Yuan Z, Li H: Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns 31, 623-628 (2005). (Pubitemid 40905221)
57. Schefold JC, von Haehling S, Corsepius M et al.: A novel selective extracorporeal intervention in sepsis: immunoabsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 28 (4), 418-425 (2007). (Pubitemid 47415252)
58. Cruz DN, Antonelli M, Fumagalli R et al.: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23), 2445-2452 (2009).
59. Tschoeke SK, Ertel W: Immunoparalysis after multiple trauma. Injury 38, 1346-1357 (2007). (Pubitemid 350192400)
60. Kylanpaa ML, Mentula P, Kemppainen E et al.: Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by granulocyte-macrophage colony-stimulating factor and interferon-γ in vitro. Pancreas 31, 23-27 (2005). (Pubitemid 40911498)
61. Flohé SB, Agrawal H, Flohé S et al.: Diversity of interferon g and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages in polymicrobial sepsis. Mol. Med. 14(5-6), 247-256 (2008). (Pubitemid 351785697)
62. Dries DJ, Jurkovich GJ, Maier RV et al.: Effect of interferon γ on infection-related death in patients with severe injuries. A randomized, double-blind placebo-controlled trial. Arch. Surg. 129(10), 1031-1041 (1994).
63. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, Steinmann GG: Interferon-γ in the prevention of severe burn-related infections: a European Phase III multicenter trial. Crit. Care Med. 26(3), 434-439 (1998). (Pubitemid 28141475)
64. Turina M, Dickinson A, Gardner S, Polk HC Jr: Monocyte HLA-DR and interferon-γ treatment in severely injured patients - a critical reappraisal more than a decade later. J. Am. Coll. Surg. 203(1), 73-81 (2006). (Pubitemid 43914487)
65. Stephens DP, Thomas JH, Higgins A et al.: Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit. Care Med. 36(2), 448-454 (2008). (Pubitemid 351158618)
66. Mohammad RA: Use of granulocyte colony-stimulating factor in patients with severe sepsis and septic shock. Am. J. Health Syst. Pharm. 67(15), 1238-1245 (2010).
67. Werdan K, Pilz G, Bujdoso O et al.: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit. Care Med. 35(12), 2693-2701 (2007). (Pubitemid 350175763)
68. Kreymann KG, de Heer G, Neirhaus A, Kluge S: Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit. Care Med. 35(12), 2677-2785 (2007). (Pubitemid 350175761)
69. Beale RJ, Sherry T, Lei K et al.: Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. Crit. Care Med. 36(1), 131-144 (2008).
70. Pérez-Bárcena J, Regueiro V, Marsé P et al.: Glutamine as a modulator of the immune system of critical care patients: effect on Toll-like receptor expression. A preliminary study. Nutrition 24, 522-527 (2008).
71. Gadek JE, DeMichele SJ, Karlstad MD et al.: Effect of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit. Care Med. 27(8), 1409-1420 (1999).
72. Pontes-Arruda A, Albuquerque Aragão AM, Albuquerque JD: Effects of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit. Care Med. 34(9), 2325-2333 (2006). (Pubitemid 44260016)
73. Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J: Benefit of an enteral diet enriched with eicosapentaenoic acid and γ-linolenic acid in ventilated patients with acute lung injury. Crit. Care Med. 34(4), 1033-1038 (2006).
74. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A et al.: Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically ill trauma patients: early results of a randomized controlled trial. World J. Surg. 30, 1848-1855 (2006). (Pubitemid 44454998)
75. Giamarellos-Bourboulis EJ, Bengmark S, Kanellakopoulou K, Kotzampassi K: Pro- and synbiotics to control inflammation and infection in patients with multiple injuries. J. Trauma 67(4), 815-821 (2009).
76. Zhang Y, Chen H, Li Y et al.: Thymosin-1 and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J. Infect. Dis. 198, 723-730 (2008).
77. Giamarellos-Bourboulis EJ: Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int. J. Antimicrob. Agents 32S, 39-43 (2008).
78. Giamarellos-Bourboulis EJ, Adamis T, Sabracos L et al.: Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Esherichia coli. Scand. J. Infect. Dis. 37, 48-54 (2005). (Pubitemid 40227740)
79. Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A et al.: Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. Int. J. Antimicrob. Agents 25, 168-172 (2005). (Pubitemid 40138955)
80. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M et al.: Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect. Dis. 6, 31-40 (2006). (Pubitemid 43380731)
81. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P et al.: Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 57, 937-944 (2006). (Pubitemid 43380731)
82. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C et al.: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis. 46, 1157-1164 (2008). nn First randomized study demonstrating a survival benefit and earlier resolution of infection after intravenous administration of clarithromycin. (Pubitemid 351589897)
83. Garcia Vázquez E, Mensa J, Martinez JA et al.: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis. 24(3), 190-195 (2005). (Pubitemid 40576665)
84. Martinez JA, Horcajada JP, Almela M et al.: Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 36(4), 389-395 (2003). (Pubitemid 36241302)